Beauty Health (SKIN)
Market Price (12/26/2025): $1.455 | Market Cap: $184.6 MilSector: Consumer Staples | Industry: Household Products
Beauty Health (SKIN)
Market Price (12/26/2025): $1.455Market Cap: $184.6 MilSector: Consumer StaplesIndustry: Household Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% | Weak multi-year price returns2Y Excs Rtn is -102%, 3Y Excs Rtn is -166% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.3% |
| Attractive yieldFCF Yield is 19% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 87% |
| Megatrend and thematic driversMegatrends include Experience Economy & Premiumization, and Health & Wellness Trends. Themes include Experiential Retail, Luxury Consumer Goods, Show more. | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 72x | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -10% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% | ||
| High stock price volatilityVol 12M is 108% | ||
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.55 | ||
| Key risksSKIN key risks include [1] costly reliability issues and performance failures with its Hydrafacial Syndeo devices and [2] persistent operating losses that have created a weak financial position. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 19% |
| Megatrend and thematic driversMegatrends include Experience Economy & Premiumization, and Health & Wellness Trends. Themes include Experiential Retail, Luxury Consumer Goods, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -102%, 3Y Excs Rtn is -166% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.3% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 87% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 72x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -10% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| High stock price volatilityVol 12M is 108% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.55 |
| Key risksSKIN key risks include [1] costly reliability issues and performance failures with its Hydrafacial Syndeo devices and [2] persistent operating losses that have created a weak financial position. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are the key points for the movement of Beauty Health (SKIN) stock from approximately August 31, 2025, to today: 1. Beauty Health reported a Q3 2025 Earnings Per Share (EPS) miss. The company reported a loss of $0.09 per share, which was worse than the estimated loss of $0.07 per share, leading to a 28.57% negative surprise for analysts. This contributed to a notable drop in stock price following the announcement.2. The company experienced a year-over-year decline in total net sales for Q3 2025. Net sales were $70.7 million, representing a 10.3% decrease compared to the same period in the previous year, primarily driven by lower sales of delivery systems and consumables.
Show more
Stock Movement Drivers
Fundamental Drivers
The -25.3% change in SKIN stock from 9/25/2025 to 12/25/2025 was primarily driven by a -22.7% change in the company's P/S Multiple.| 9252025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.94 | 1.45 | -25.26% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 310.06 | 301.92 | -2.63% |
| P/S Multiple | 0.79 | 0.61 | -22.74% |
| Shares Outstanding (Mil) | 126.07 | 126.89 | -0.65% |
| Cumulative Contribution | -25.26% |
Market Drivers
9/25/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| SKIN | -25.3% | |
| Market (SPY) | 4.9% | 31.4% |
| Sector (XLP) | 0.5% | 20.7% |
Fundamental Drivers
The -25.3% change in SKIN stock from 6/26/2025 to 12/25/2025 was primarily driven by a -19.0% change in the company's P/S Multiple.| 6262025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.94 | 1.45 | -25.26% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 322.47 | 301.92 | -6.37% |
| P/S Multiple | 0.75 | 0.61 | -19.01% |
| Shares Outstanding (Mil) | 125.08 | 126.89 | -1.45% |
| Cumulative Contribution | -25.27% |
Market Drivers
6/26/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| SKIN | -25.3% | |
| Market (SPY) | 13.1% | 29.5% |
| Sector (XLP) | -1.9% | 25.5% |
Fundamental Drivers
The -2.7% change in SKIN stock from 12/25/2024 to 12/25/2025 was primarily driven by a -13.1% change in the company's Total Revenues ($ Mil).| 12252024 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.49 | 1.45 | -2.68% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 347.62 | 301.92 | -13.15% |
| P/S Multiple | 0.53 | 0.61 | 14.61% |
| Shares Outstanding (Mil) | 124.06 | 126.89 | -2.28% |
| Cumulative Contribution | -2.74% |
Market Drivers
12/25/2024 to 12/25/2025| Return | Correlation | |
|---|---|---|
| SKIN | -2.7% | |
| Market (SPY) | 15.8% | 28.6% |
| Sector (XLP) | 0.2% | 19.1% |
Fundamental Drivers
The -84.0% change in SKIN stock from 12/26/2022 to 12/25/2025 was primarily driven by a -84.5% change in the company's P/S Multiple.| 12262022 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.04 | 1.45 | -83.96% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 345.63 | 301.92 | -12.65% |
| P/S Multiple | 3.94 | 0.61 | -84.55% |
| Shares Outstanding (Mil) | 150.79 | 126.89 | 15.85% |
| Cumulative Contribution | -84.36% |
Market Drivers
12/26/2023 to 12/25/2025| Return | Correlation | |
|---|---|---|
| SKIN | -55.2% | |
| Market (SPY) | 48.3% | 31.7% |
| Sector (XLP) | 14.4% | 18.6% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SKIN Return | - | 88% | -62% | -66% | -49% | -9% | -89% |
| Peers Return | 5% | 37% | -34% | 9% | -5% | 39% | 36% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| SKIN Win Rate | - | 75% | 33% | 42% | 33% | 42% | |
| Peers Win Rate | 56% | 60% | 44% | 52% | 46% | 58% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SKIN Max Drawdown | - | -7% | -65% | -85% | -64% | -48% | |
| Peers Max Drawdown | -48% | -6% | -49% | -19% | -24% | -30% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ABBV, BHC, HOLX, APYX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | SKIN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.3% | -25.4% |
| % Gain to Breakeven | 2021.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to IPAR, CENT, CL, KMB, CHD
In The Past
Beauty Health's stock fell -95.3% during the 2022 Inflation Shock from a high on 11/2/2021. A -95.3% loss requires a 2021.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
AI Analysis | Feedback
Here are a couple of analogies for Beauty Health (SKIN):
Align Technology (Invisalign) for non-invasive skin treatments. (Both sell a proprietary system of devices and recurring consumables through professionals for aesthetic enhancements.)
Keurig for professional skincare devices. (Both utilize a "razor and blade" model, selling a core device and then generating recurring revenue from proprietary consumables.)
AI Analysis | Feedback
- HydraFacial Delivery Systems: Professional aesthetic devices used by estheticians and dermatologists to perform multi-step facial treatments.
- HydraFacial Consumables: Proprietary serums, tips, and other single-use products essential for performing HydraFacial treatments.
- Perk Skincare System: A two-in-one treatment and take-home product system designed for the eyes and lips, often used in conjunction with HydraFacial.
AI Analysis | Feedback
The Beauty Health Company (SKIN) primarily sells its products and services to other businesses (B2B) rather than directly to individuals. Its major customers are professional aesthetic providers who then offer treatments to end-consumers.
Based on the company's public filings, its customer base is highly fragmented. Therefore, specific names of major customer companies that are publicly traded or represent a significant portion of Beauty Health's revenue are not disclosed. The company's 2023 Annual Report on Form 10-K states that sales to its largest customer represented less than 10% of consolidated net sales, indicating no single dominant customer. As such, no specific public company symbols can be provided for major customers.
The types of businesses that constitute Beauty Health's customer base include:
- Physician offices (such as dermatologists and plastic surgeons)
- Medical spas (medspas)
- Independent aesthetic practices and licensed aestheticians
- Other businesses offering aesthetic treatments
Additionally, Beauty Health sells its products internationally through a network of independent distributors, who also serve as B2B customers.
AI Analysis | Feedback
null
AI Analysis | Feedback
Pedro Malha, President and Chief Executive Officer
Pedro Malha brings over two decades of global leadership experience in the healthcare and medical device industries. He most recently served as Worldwide Division President and Corporate Officer of Abbott Laboratories, where he led the neuromodulation business. Prior to that, he held senior leadership roles overseeing multiple global business units at Zimmer Biomet Holdings, Abbott, and Johnson & Johnson, consistently delivering growth and operational excellence.
Michael Monahan, Chief Financial Officer
Michael Monahan has nearly 15 years of experience as a public and private company CFO and over 25 years of accounting and financial management experience. He previously served as CFO of Casper Sleep (NYSE: CSPR) following its IPO, and as CFO of Nutrisystem (NASDAQ: NTRI), where he quintupled its market cap and oversaw a key acquisition. He began his career in the commercial audit practice of Arthur Andersen LLP.
Ron Menezes, Chief Revenue Officer
Ron Menezes is responsible for BeautyHealth's global sales operations and growth. He is a seasoned executive with over 20 years of leadership experience in product commercialization and revenue generation at premier aesthetics, dermatology, and medical device companies, as well as high-growth startups. Before joining BeautyHealth, Ron was the President and CEO of Sientra, where he successfully revamped the company's go-to-market strategy, expanded its market presence, and drove substantial revenue growth.
Celeste Ortiz, Chief Human Resources Officer
As Chief Human Resources Officer, Celeste Ortiz is dedicated to enabling growth through a strong people agenda. She previously held progressive HR leadership roles at healthcare companies Pfizer, Johnson & Johnson, and Medtronic Diabetes. Most recently, she served as Chief People Officer of the high-growth startup Crossover Health, where she scaled the workforce tenfold. She is a member of the Board of Directors for SCAN and Ideal Image.
Sheri Lewis, Chief Supply Chain and Operations Officer
Sheri Lewis oversees global supply chain strategies for BeautyHealth. She has leadership experience at Avantor and Medtronic, contributing to enhanced operational performance.
AI Analysis | Feedback
The Beauty Health Company (SKIN) faces several significant risks to its business, primarily stemming from product reliability issues, ongoing financial losses, and an intensely competitive market.
- Device Reliability and Product Issues: A key risk for Beauty Health is the recurring problems with its Hydrafacial Syndeo devices. These issues have included "frequent treatment interruptions" and reliability concerns, leading to increased warranty and replacement costs, significant restructuring charges, and inventory write-downs. The company has also faced an investor lawsuit alleging that it concealed these device problems. Such product performance issues have directly contributed to lower-than-expected U.S. revenue, a reduction in financial guidance, and a substantial drop in the company's stock value.
- Operating Losses and Weak Financial Health: Beauty Health has consistently reported operating losses and a declining earnings per share (EPS). Over the past two years, the company has experienced a negative average operating margin due to high expenses. Furthermore, it has a short cash runway and its debt exceeds its cash on hand, raising concerns about its ability to fund operations without potential shareholder dilution through future capital raises.
- Intense Competition and Evolving Market Dynamics: The beauty and aesthetics industry, where Beauty Health operates, is highly dynamic and competitive. The company faces direct competition from other hydradermabrasion devices, as well as broader competitive pressures from energy-platform vendors and emerging trends like AI skin imaging and personalization software. This competitive landscape can exert significant pressure on pricing and demand for Beauty Health's products and services.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Beauty Health's main products and services are significant across several categories:
- HydraFacial: The global addressable market for HydraFacial is estimated at more than 500,000 potential locations. Beauty Health, through its HydraFacial brand, operates within the global facial aesthetics market, which is valued at over $15 billion. As of June 2025, over 35,000 HydraFacial devices have been installed worldwide.
- Skincare Devices (including HydraFacial, SkinStylus microneedling devices, and potentially Keravive devices): The global skincare devices market size was estimated at USD 19.22 billion in 2024 and is projected to increase to approximately USD 53.72 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 10.83% from 2025 to 2034. In North America, the skincare devices market size was USD 9.03 billion in 2024 and is expanding at a CAGR of 10.85% during the forecast period of 2025-2034. The U.S. skincare devices market was valued at USD 6.25 billion in 2024 and is projected to reach around USD 18.30 billion by 2034, with a CAGR of 11.34% from 2025 to 2034.
- Professional Skincare (encompassing HydraFacial, SkinStylus, and Keravive treatments and consumables): The global professional skincare market size was approximately USD 43.14 billion in 2024 and is expected to grow to USD 57.54 billion by 2029, with a CAGR of 6.0%. Another estimate projects this market to reach USD 59.91 billion by 2029 with a CAGR of 6.7%.
AI Analysis | Feedback
Beauty Health (NASDAQ: SKIN) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Growth in Consumables and New Booster Products: The company's "razor-blade" business model heavily relies on its high-margin consumable products. There has been a notable increase in the consumable mix as a percentage of net sales, with consumables revenue growing even amidst declines in device sales. Successful new product launches, such as Hydralock HA and HydraFillic with Pep9 Boosters, have contributed to double-digit growth in the booster sales category, underscoring the company's innovation capabilities and its focus on recurring revenue.
- Expansion of Hydrafacial Installed Base: A core component of Beauty Health's strategy is to protect and expand its Hydrafacial installed base. An increasing number of active Hydrafacial delivery systems in the field directly correlates with higher utilization of consumables. As of Q3 2025, the total active machines in the field increased to 35,409 units from 34,162 units the previous year, indicating a growing foundation for future consumable sales.
- Launch of New Products and Innovations: Beauty Health continuously focuses on innovating across its platforms. Upcoming product launches, including new skincare and device innovations, are anticipated to drive future growth by offering advanced solutions that resonate with the market and keep the brand competitive.
- Global Market Expansion: The company is strategically focused on expanding its global footprint. While facing some regional challenges, such as the transition to a distributor model in China, Beauty Health has shown strong performance in other international markets like Germany, contributing to its overall global expansion efforts. Increasing the number of devices in use across various geographies is a stated strategy to fuel long-term consumables demand.
- Strategic Price Increases: Beauty Health has demonstrated its ability to implement price adjustments. The company executed its first price increase in three years, which contributed to improved financial results and is expected to continue to play a role in revenue growth.
AI Analysis | Feedback
Share Repurchases
- The company repurchased approximately $170 million aggregate principal amount of its 2026 convertible senior notes for approximately $161 million in the second quarter of 2025.
- In the first half of 2025, Beauty Health repurchased approximately $20 million of principal of its 2026 notes as part of a convertible note exchange.
- Beauty Health repurchased and retired $30.2 million worth of its shares during the fourth quarter of 2023, resulting in an approximate 8% decline in share count.
Share Issuance
- The company issued $250.0 million of 7.95% Convertible Senior Secured Notes due 2028 in the third quarter of 2025.
- The number of Class A shares outstanding has generally decreased from 132,500,049 as of February 24, 2023, to 127,503,059 as of November 3, 2025.
Capital Expenditures
- Beauty Health planned investments in systems, processes, and training during 2024 to enhance supply chain and inventory management.
- The company exited a third-party manufacturing arrangement in 2024 and plans to transition its China market from a direct sales model to a distributor model in 2025.
- The company is implementing a "good, better, best device strategy" to expand provider access by offering select systems at lower price points, influencing capital allocation toward device innovation and market penetration.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Beauty Health Earnings Notes | ||
| Would You Still Hold Beauty Health Stock If It Fell 30%? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SKIN. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -6.5% | -6.5% | -7.4% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -8.1% | -8.1% | -9.2% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 13.2% | 13.2% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 5.2% | 5.2% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.3% | -5.3% | -6.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Beauty Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.18 |
| Mkt Cap | 2.7 |
| Rev LTM | 4,100 |
| Op Inc LTM | 785 |
| FCF LTM | 905 |
| FCF 3Y Avg | 450 |
| CFO LTM | 1,057 |
| CFO 3Y Avg | 780 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.7% |
| Rev Chg 3Y Avg | -0.5% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | 19.1% |
| Op Mgn 3Y Avg | 18.2% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 15.3% |
| CFO/Rev 3Y Avg | 8.0% |
| FCF/Rev LTM | 11.3% |
| FCF/Rev 3Y Avg | 4.4% |
Price Behavior
Price Behavior
| Market Price | $1.45 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 05/06/2021 | |
| Distance from 52W High | -44.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.41 | $1.61 |
| DMA Trend | indeterminate | down |
| Distance from DMA | 2.8% | -9.9% |
| 3M | 1YR | |
| Volatility | 68.4% | 108.8% |
| Downside Capture | 217.13 | 220.69 |
| Upside Capture | 32.80 | 187.18 |
| Correlation (SPY) | 31.9% | 28.7% |
SKIN Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.77 | 2.16 | 2.52 | 2.65 | 1.68 | 1.67 |
| Up Beta | -0.29 | 2.58 | 2.22 | 3.99 | 0.72 | 0.22 |
| Down Beta | 1.09 | 1.58 | 1.41 | 1.82 | 2.45 | 2.42 |
| Up Capture | 289% | 88% | 173% | 228% | 349% | 442% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 15 | 24 | 48 | 108 | 333 |
| Down Capture | 213% | 287% | 341% | 252% | 147% | 111% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 25 | 35 | 68 | 124 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 8.5% | 0.8% | 17.8% |
| 8/7/2025 | 18.9% | 36.5% | 46.5% |
| 3/12/2025 | -5.6% | -7.0% | -29.6% |
| 11/12/2024 | 8.8% | -5.0% | -11.2% |
| 8/8/2024 | -13.2% | 8.5% | 4.7% |
| 3/12/2024 | 18.4% | 9.7% | 5.8% |
| 11/13/2023 | -64.4% | -40.0% | -21.3% |
| 8/9/2023 | -5.4% | -18.1% | -23.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 8 |
| # Negative | 9 | 8 | 9 |
| Median Positive | 11.3% | 9.7% | 22.8% |
| Median Negative | -12.0% | -9.0% | -19.5% |
| Max Positive | 28.8% | 48.8% | 46.5% |
| Max Negative | -64.4% | -40.0% | -29.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8072025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 3122025 | 10-K 12/31/2024 |
| 9302024 | 11122024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 3122024 | 10-K 12/31/2023 |
| 9302023 | 11142023 | 10-Q 9/30/2023 |
| 6302023 | 8092023 | 10-Q 6/30/2023 |
| 3312023 | 5102023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11092022 | 10-Q 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5102022 | 10-Q 3/31/2022 |
| 12312021 | 3012022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.